创新药受益于BD预期带动,年初至7月医药指数大涨,8月至今震荡调整,行业整体估值处于历史平均偏低水平。编辑|白鹿投顾支持 | 于晓明执业证书编号:A0680622030012特别提示通过本公众号发布的观点和信息仅供陕西巨丰投资资讯有限责任公司(下称“巨丰投顾”)客户中符合《证券期货投资者适当性管理办法》规定的特定客户参考。因本公众号暂时无法设置访问限制,若您并非巨丰投顾客户,为控制投资风险,请您...
Source Link创新药受益于BD预期带动,年初至7月医药指数大涨,8月至今震荡调整,行业整体估值处于历史平均偏低水平。编辑|白鹿投顾支持 | 于晓明执业证书编号:A0680622030012特别提示通过本公众号发布的观点和信息仅供陕西巨丰投资资讯有限责任公司(下称“巨丰投顾”)客户中符合《证券期货投资者适当性管理办法》规定的特定客户参考。因本公众号暂时无法设置访问限制,若您并非巨丰投顾客户,为控制投资风险,请您...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.